Blood · 2008 · 123 citations · 8 references
MedicineOncologyPharmacologyCancer PharmacologyChemotherapyMolecular OncologyMtor Inhibitor TherapyTargeted Cancer TherapyTargeted TherapyAcute Leukemia ChemotherapyAcute Lymphoblastic Leukemia TherapyAcute Lymphoblastic Leukemia TreatmentMtor InhibitionMtor SignalingRefractory Acute Lymphoblastic Leukemia
We have previously demonstrated that mTOR inhibitors (MTIs) are active in preclinical models of acute lymphoblastic leukemia (ALL). MTIs may increase degradation of cyclin D1, a protein involved in dihydrofolate reductase (DHFR) synthesis. Because resistance to methotrexate may correlate with high DHFR expression, we hypothesized MTIs may increase sensitivity of ALL to methotrexate through decreasing DHFR by increasing turn-over of cyclin D1. We tested this hypothesis using multiple ALL cell lines and nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice xenografted with human ALL. We found MTIs and methotrexate were synergistic in combination in vitro and in vivo. Mice treated with both drugs went into a complete and durable remission whereas single agent treatment caused an initial partial response that ultimately progressed. ALL cells treated with MTIs had markedly decreased expression of DHFR and cyclin D1, providing a novel mechanistic explanation for a combined effect. We found methotrexate and MTIs are an effective and potentially synergistic combination in ALL.
8
Functional interactions of the retinoblastoma protein with mammalian D-type cyclins
Mark E. Ewen, Hayla K. Sluss, C J Sherr et al. · Cell · 1993 · 1K citations
Sergei A. Ezhevsky, Alan L. Ho, Michelle Becker‐Hapak et al. · Molecular and Cellular Biology · 2001 · 207 citations · Full text